Bayer’s Yaz and blood clots – the legal wrangling continues.
Solvay selling out on pharma, narrows it down to 2 bidders – Solvay has whittled down the list of bidders for its pharmaceuticals business to Nycomed, the privately held Swiss company, and Abbott Laboratories of the US…more
Transplant drugs have to alter labels to include increased risks – The U.S. Food and Drug Administration today said that it will require manufacturers of some immunosuppressant drugs used in kidney (renal) transplantation to update their labeling to reflect an increased risk of infections…more
More bad news on hormone therapy – Women who took hormone replacement therapy after menopause had a sharply increased risk of ovarian cancer, researchers in Denmark are reporting…more
It’s very early, but this Roche potential cancer drug shows some interesting promise. Glioblastoma is a real problem, in need of some new therapies. And, speaking of early, here’s a very counter-intuitive positive result for an Alzheimer’s treatment. Like, 180-degrees counter-intuitive!
PLUS: From Forrester Research – How to Create a Social Application for Life Sciences without Getting Fired ($$ report).
AND: What are the pharma company early adopters doing on Twitter? Here’s the overview, with stats.
Subscribe to the Impactiviti blog via e-mail
Subscribe to the Impactiviti blog via RSS
Connect with Steve Woodruff